Your browser doesn't support javascript.
loading
CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.
Crucitta, Stefania; Del Re, Marzia; Paolieri, Federico; Bloise, Francesco; Sbrana, Andrea; Sammarco, Enrico; Mercinelli, Chiara; Cucchiara, Federico; Fontanelli, Lorenzo; Galli, Luca; Danesi, Romano.
Afiliación
  • Crucitta S; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, 55, Via Roma, 56126, Pisa, Italy.
  • Del Re M; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, 55, Via Roma, 56126, Pisa, Italy. marzia.delre@gmail.com.
  • Paolieri F; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Bloise F; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Sbrana A; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Sammarco E; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Mercinelli C; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Cucchiara F; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, 55, Via Roma, 56126, Pisa, Italy.
  • Fontanelli L; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, 55, Via Roma, 56126, Pisa, Italy.
  • Galli L; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Danesi R; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, 55, Via Roma, 56126, Pisa, Italy.
Cancer Chemother Pharmacol ; 86(4): 527-533, 2020 10.
Article en En | MEDLINE | ID: mdl-32945940
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Esteroide 17-alfa-Hidroxilasa / Adenocarcinoma / Biomarcadores de Tumor / Resistencia a Antineoplásicos / Neoplasias de la Próstata Resistentes a la Castración / Acetato de Abiraterona Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancer Chemother Pharmacol Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Esteroide 17-alfa-Hidroxilasa / Adenocarcinoma / Biomarcadores de Tumor / Resistencia a Antineoplásicos / Neoplasias de la Próstata Resistentes a la Castración / Acetato de Abiraterona Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancer Chemother Pharmacol Año: 2020 Tipo del documento: Article